Alkermes, Inc. and Lilly have signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone (PTH). The development program will utilize the Alkermes AIR pulmonary drug delivery system. Lilly’s recombinant PTH, Forteo injection, was approved in 2002 by the FDA for the treatment of osteoporosis in postmenopausal women who are at high risk for bone fracture and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fractur...